Cipla unveils Pirfenidone for IPF patients in India
Pirfenidone is a novel anti-fibrotic drug which through clinical trials has shown to slow down progression of this terminal disease and stabilize lung function. Cipla said that Pirfenex
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
The patents cover oral formulations of leading injectables, like bevacizumab (Avastin), trastuzumab (Herceptin), adalimumab (Humira, etanercept (Enbrel), insulin glargine (Lantus), and many others. In addition, Access rebranded its